Forward-Looking Statements

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

2026-04-21

NewcelX Ltd. ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) — NewcelX Ltd. (Nasdaq: NCEL),– NewcelX Ltd. (Nasdaq: NCEL),…

VVitol

GeoPark Renews Offtake Agreement With Vitol in Colombia

2026-04-19

Improved Price Realizations and Lower-cost Flexible Funding of up to $500 Million BOGOTA, Colombia, January 28, 2026–(BUSINESS WIRE)–GeoPark…

GGlencore

Military Metals Announces Former CEO of Glencore Nordenham Germany as Chairman and Director

2026-03-26

Vancouver, British Columbia–(Newsfile Corp. – March 26, 2026) – Military Metals Corp (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the…

NNovartis

2026-03-17

Novartis Pharma AG Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading…

NNovartis

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

2026-03-08

Novartis Pharma AG Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing…

NNovartis

2026-03-06

Novartis Pharma AG Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing…

NNovartis

2026-03-06

Novartis Pharma AG Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing…

RRoche

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

2026-02-26

CHICAGO, June 18, 2025–(BUSINESS WIRE)–MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted…